Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
11/25 GILEAD SCIENCES : Zydelig® Combined with Bendamustine and Rituximab Shows Superi..
11/24 GILEAD SCIENCES : to Present at Two Upcoming Investor Conferences on Tuesday, De..
11/23 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead&..
11/19 GILEAD SCIENCES : U.S. FDA Approves New Indications for Harvoni®, Gilead's Once-..
11/19 GILEAD SCIENCES : X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead S..
11/17 European biotech gets boost as Genmab market value hits $7 billion
11/16 GILEAD SCIENCES : Gileand Sciences - Briefing
11/16 GILEAD SCIENCES : Zydelig® Combined with Bendamustine and Rituximab Shows Superi..
11/16 GILEAD SCIENCES : Briefing
11/14 GILEAD SCIENCES : Multiple Scientific Presentations at The Liver Meeting 2015 Fu..
News chart
Full-screen chart
Income Statement Evolution
More Financials